Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

United States Generic Drugs Market Report 2023-2028 Featuring Major Players - Teva Pharma, Aurobindo Pharma, Sun Pharma, Abbott Laboratories, Lupin Pharmaceuticals, Viatris, Sandoz, & Dr. Reddy's

Research and Markets Logo

News provided by

Research and Markets

Jul 05, 2023, 14:00 ET

Share this article

Share toX

Share this article

Share toX

DUBLIN, July 5, 2023 /PRNewswire/ -- The "United States Generic Drugs Market, Forecast 2023-2028, Industry Trends, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to  ResearchAndMarkets.com's offering.

United States Generic Drugs Market is projected to reach around US$ 147.57 Billion by 2028 from $101 Billion in 2022, and is expected to grow at a CAGR of 6.39% from 2022 to 2028

The pharmaceutical industry is vital for global healthcare, but it is important to distinguish between factors driving cost increases and those generating savings. Specialty drugs, including biologics, are expensive drugs used for treating complex diseases. However, generic drugs in the US have offered relief from rising drug costs for decades, as competition drives down prices. Generics are cheaper off-patented drugs that are bioequivalent to branded medications.

In the US, they have risen in production due to cost-effectiveness and increased patient access, generating savings for taxpayers, employers, and insurance providers. The number of generic drug approvals has risen, supported by the FDA's Drug Competition Action Plan and the reauthorization of the Generic Drug User Fee Amendments in 2017 to enhance the generic drug development and approval process. In 2022, 91% of US prescriptions were generic drugs, with over 32,000 FDA-approved generic drugs available, partially offsetting large brand drug price increases.

Increasing Prevalence of Life-threatening Diseases in the United States is creating Future Opportunities for the Generic Drug Market

The generic drug market in the United States is witnessing substantial expansion, driven by the growing incidence of chronic illnesses like cardiovascular disease, diabetes, Alzheimer's disease, and Parkinson's disease in the region.

The FDA's Generic Drug Program carries out thorough assessments before approval to guarantee that generic medications comply with these guidelines. Moreover, the FDA inspects manufacturing facilities to verify their adherence to agency regulations on good manufacturing practices.

Demand for Branded Generics has been rising in USA, due to the Increasing need for Affordable, High-quality Generic Drugs and the Soaring Healthcare Costs

By Type, United States Generic Drugs Market is segmented into Branded Generics and Unbranded Generics. The growth of the branded generics pharmaceutical industry in the USA is being driven by factors such as moderately high penetration of these drugs and an increasing disease burden among the geriatric population.

Branded generics drugs provide a cost-efficient substitute to costly branded drugs, which is particularly significant in United States with expensive healthcare. Furthermore, the expiration of patents on numerous popular drugs has opened doors for generic drug makers to join the market and provide more affordable options. The industry is also backed by government policies that encourage the use of generics to decrease healthcare expenses.

Inclination towards Generic Drugs to treat heart disease is expected to continue in the United States Pharmaceutical Market

United States Generic Drugs Industry is classified into various therapeutic areas, including Heart Disease, Mental Health, Diabetes, Epilepsy, Cancers, Allergies & Asthma, Chronic Obstructive Pulmonary disease, Alzheimer's disease, HIV/AIDS, and Crohn's Colitis. The demand for generic drugs to treat heart disease is growing due to factors such as the higher occurrence of heart disease, patent expiration of brand-name drugs, and the need for accessible healthcare.

The use of generic drugs for heart disease treatment is being promoted by government policies like the Affordable Care Act. Despite being more affordable, generic drugs are equally safe and effective as brand-name drugs and healthcare providers and patients are turning to them, with statins, beta-blockers, and ACE inhibitors being some of the most frequently prescribed.

Oral and Injectable Generic Drugs markets will continue to grow Simultaneously in the Upcoming Years

By Drug Delivery, USA Generic Drugs Market is divided into Oral, Injectable, Dermal/Topical and Inhalers. Oral and Injectable market share will grow simultaneously in upcoming years, as the demand for affordable and accessible healthcare continues to increase. Factors such as patent expirations of brand-name drugs, increasing healthcare costs, and rising demand for biosimilars may contribute to the growth of both oral and injectable generic drug markets.

Oral generics are widely used and expected to grow due to increasing launches and partnerships like OakrumPharma and ANI Pharmaceuticals' collaboration to create a generic version of Cystadane1, approved by the USFDA in February 2022, which is expected to boost sales and production of oral generics.

Growing emphasis on Self-care and over-the-counter Medications has also contributed to the growth of the U.S. Retail Pharmacy Generic Drugs Market

The US Generic Drugs Industry is fragmented into Specialty Pharmacy, Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy. Retail pharmacy has traditionally dominated the distribution channel segment, with patients preferring to purchase medications from physical stores.

The retail pharmacy market has been steadily growing due to patent expirations of branded drugs, increasing healthcare costs, and rising demand for affordable medications. The availability of cheaper generic medicines has led to widespread adoption, especially for chronic diseases like diabetes, cardiovascular diseases, and cancer, which have driven demand for generic drugs.

The shift towards online pharmacy channels and the increasing use of e-prescriptions are also expected to drive the growth of the retail pharmacy generic drugs market in the coming years. There has been a surge in online shopping, including the online distribution of pharmaceutical products.

Growth of the Generic Drugs Market for Adults is the increasing adoption of Biosimilars

By Age Group, USA Generic Drugs Market subdivided into Children (0-19 years), Young Adults (20-39 years), Adults (40-64 years) and seniors (65+ years). The generic drugs market for adults in the United States has been growing steadily over the past few years. In 2022, generic drugs accounted for over 91% of all prescriptions dispensed in the United States.

This indicates a strong demand for affordable medications, which is a key driver of the growth of the generic drugs market. One of the major factors contributing to the growth of the generic drugs market for adults in the US is the increasing number of patent expiries of branded drugs used to treat adult diseases such as cardiovascular disease, diabetes, and cancer.

Key Players Analysis

To stay competitive in the growing market, industry participants are utilizing various tactics including increased investment in research and development, mergers and acquisitions, and product innovations.

Major players in the market include Teva Pharmaceuticals, Aurobindo Pharma, Sun Pharmaceuticals, Abbott Laboratories Inc., Lupin Pharmaceuticals Inc., Viatris, Sandoz, and Dr. Reddy's.

Company Analysis: Overview, Recent Developments, Revenue Analysis

  • Teva Pharmaceuticals
  • AurobindoPharma
  • Sun Pharmaceuticals
  • Abbott Laboratories Inc
  • Lupin Pharmaceuticals Inc
  • Viatris
  • Sandoz
  • Dr. Reddy's.

Type: Market breakup in 2 viewpoints

  • Branded Generics
  • Unbranded Generics

Therapeutic Area: Market breakup from 10 viewpoints

  • Heart Disease
  • Mental Health
  • Diabetes
  • Epilepsy
  • Cancers
  • Allergies & Asthma
  • Chronic Obstructive Pulmonary Disease
  • Alzheimer Disease
  • HIV/AIDS
  • Crohn's colitis

Drug Delivery: Market breakup from 4 viewpoints

  • Oral
  • Injectable
  • Dermal/Topical
  • Inhalers

Distribution Channel: Market breakup from 4 viewpoints

  • Specialty Pharmacy
  • Retail Pharmacy
  • Hospital Pharmacy
  • Online Pharmacy

Age Group: Market breakup from 4 viewpoints

  • Children (0-19 years)
  • Young Adults (20-39 years)
  • Adults (40-64 years)
  • Seniors (65+ years)

States: Market breakup from 11 States

  • California
  • Texas
  • New York
  • Florida
  • Pennylavania
  • Ohio
  • Illionios
  • North Carolina
  • Georgia
  • Michigan
  • Others

Payment Type: Market breakup from 4 viewpoints

  • Cash
  • Commercial
  • Medicare D
  • Medicaid

Frequency in consumption of Generic Drugs in United States

  • At least 1 prescription generic drugs consumption monthly
  • Three or more prescription generic drugs consumption monthly
  • Five or more Prescription generic drugs consumption monthly

For more information about this report visit https://www.researchandmarkets.com/r/1x99by

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]    

For E.S.T Office Hours Call +1-917-300-0470 
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716 

Logo:  https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg 

SOURCE Research and Markets

21%

more press release views with 
Request a Demo

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.